

Freedom of Information Act 2000 – Request Reference FoI/24/257

Psychedelic Consumption

Information Requested:

- 1) How many times 'microdosing' psychedelic substances was included as a reason for admissions to your hospitals in 2022, 2023 and 2024 to date.
- 2) How many times the consumption of psychedelic substances in any quantity was included as a reason for admissions to your hospitals in 2022, 2023 and 2024 to date.

Such substances include but are not limited to:

- Magic Mushrooms (e.g. Psilocybin)
- MDMA
- LSD
- DMT
- Ayahuasca (e.g. Harmaline)
- Salvia

Please break this down by drug, year and patient age.

Response Details:

In response to point 1

Please see the below table for the number of admitting episodes from 1 January 2022 to date being coded with Psilocybin (T40.9), MDMA (T43.6), LSD (T40.8), DMT (T40.9) Ayahuasca (T40.9), Salvia (T40.9). Please note that several substances use the same ICD code.

Year	Number of Admissions with a Specified Substance Abuse
2022	6
2023	7
2024	3
Total	16

In response to point 2

Please see the below table for the number of hospital stays for the same coded substances as above from 1 January 2022 to date.

Number of Hospital Stays	2022	2023	2024
MDMA	5	7	2
LSD	1	0	0
Psilocybin/DMT/Ayahuasca/Salvia	1	0	1

Please note that a patient was coded with both an MDMA and a Psilocybin/DMT/Ayahuasca/Salvia related admission. Please also note that the above information is derived from coded clinical data, which represents the main condition treated or investigated during the relevant episode of healthcare rather than the reason for admission.